The University of Michigan is getting $65.6 million for a portion of its royalty interest in a capsule-based drug to treat Gaucher's disease, and an Incline Village based company will be reaping the benefits. Under the terms of the agreement, PDL will get 75 percent of royalty payments due under the University of Michigan's license agreement with Genzyme Corp. until expiration of the licensed patents, excluding any patent extension.